Video

Dr. Goetz on the Clinical Significance of Lasofoxifene in ER+/HER2- Breast Cancer

Matthew P. Goetz, MD, discusses the clinical significance of the phase 2 ELAINE-1 trial of lasofoxifene in patients with ESR1-mutated, estrogen receptor-positive/HER2-negative metastatic breast cancer.

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the clinical significance of the phase 2 ELAINE-1 trial (NCT03781063) of lasofoxifene in patients with ESR1-mutated, estrogen receptor (ER)–positive/HER2-negative metastatic breast cancer.

ELAINE-1 evaluated the safety and efficacy of lasofoxifene vs fulvestrant (Faslodex) in this patient population. Lasofoxifene demonstrated clear evidence of antitumor activity as monotherapy in ELAINE-1, Goetz says. Additionally, the combination of lasofoxifene and abemaciclib (Verzenios) demonstrated activity in patients with ESR1-mutated, ER-positive/HER2-negative advanced breast cancer who progressed on a CDK4/6 inhibitor during the phase 2 ELAINE-2 trial (NCT04432454), Goetz explains.

Additional trials evaluating lasofoxifene and other selective estrogen receptor modulators will be critical for the further development of these agents, Goetz continues. The overarching goal is to develop improved therapies to treat patients with ESR1 mutations and potentially prevent them, Goetz concludes. 

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity